Therapeutics

#Biotechnology #Life sciences #Pharma #Report #Therapeutics

Report shows growth in advanced therapeutics in Stockholm

A new report from Invest Stockholm on Advanced Therapeutics Manufacturing and Life Science in the Stockholm region showed that the sector has grown by 66% in the past four years. Collaboration between local tech and pharma industries are expected to further enhance Stockholm’s competitiveness and growth in the future. Both… Read More

#Editor's Choice #News #Trending News

#Cancer research #Drug development #Therapeutics

Vivan Therapeutics joins global Repositive Cancer Model network

Repositive has announced that UK-based personalised therapeutics company Vivan Therapeutics will join its network of cancer model partners. Vivan Therapeutics is a personalised therapeutics company that engineers drosophila ‘avatar’ models for cancer research and development. Its technology engineers the genetic complexity of a cancer patient’s unique tumour network (up to… Read More

#Cancer Research #News

#Drug development #Drug discovery #Gene therapy #Therapeutics

Geneticist launches Axovia Therapeutics to develop medicines for ciliopathies

Axovia Therapeutics, a gene therapy company developing disease-transformative medicines for ciliopathies, led by researcher Professor Philip Beales, has launched after being in stealth mode for the past year. Axovia is a majority-owned subsidiary of Jaguar Gene Therapy, and is partially funded by UCL Technology Fund. Axovia is receiving initial operational… Read More

#Editor's Choice #News

#Biopharmaceuticals #Covid-19 #Podcast #Therapeutics

How critical is the part therapeutics in the COVID-19 pandemic? – podcast

The latest DDW Sitting Down With podcast features Guy Goldberg, Chief Business Officer of RedHill Biopharma. RedHill Biopharma  is a biopharmaceutical company that recently announced the dosing of the first patient in its US Phase II/III study of orally-administered RHB-107 (upamostat), an investigational new drug for patients with symptomatic COVID-19… Read More

#Covid-19 #Editor's Choice #News

#Coronavirus #Covid-19 #Drug development #Drug discovery #Immunology / Virology & Vaccines #Pandemic #Sitting Down With #Therapeutics

How critical is the part therapeutics have to play in the pandemic?

This DDW Sponsored Sitting Down With episode features Guy Goldberg, Chief Business Officer of RedHill Biopharma. In this episode  – Guy Goldberg discusses COVID-19 therapeutics and their role in the pandemic. Goldberg shares his market insight, the benefits of an orally-administered small molecule tablet for COVID treatment and how the… Read More

#Podcasts

#Anti-virals #Covid-19 #Interferons #Therapeutics

Inventor of synthetic Interferon discusses potential against COVID-19

ILC Therapeutics, a biotech company based in Scotland, is developing a synthetic Interferon which has shown great promise against COVID-19 in laboratory testing and will enter clinical trials later this year. It will be, says the company, the first synthetic Interferon based on the most prominent activities of the natural… Read More

#Covid-19 #Editor's Choice #Exclusive Content #Opinion

#Immuno-oncology #T-Cells #Therapeutics

T-Cypher Bio separates from Orbit Discovery to build a pipeline of TCR therapeutics

T-Cypher Bio, a biotech company pioneering a novel approach to (T cell receptor) TCR therapeutics has separated from Orbit Discovery to focus on developing a functional, high-throughput, bead-display platform to select therapeutically relevant targets and identify potent, target-specific TCRs for the treatment of solid tumours and other indications. The formation… Read More

#News

#Clinical trials #Therapeutics

Clinical trial shows potential of MDMA therapy for addiction

Awakn Life Sciences has published results from its CMO Dr Ben Sessa’s Bristol Imperial MDMA in Alcoholism (BIMA) trial, an open-label safety, tolerability and proof-of-concept study investigating the potential role for MDMA therapy in treating patients with alcohol use disorder (AUD). Results published in the Journal of Psychopharmacology, show that… Read More

#Editor's Choice #News

#Biopharmaceuticals #Covid-19 #Therapeutics

RedHill Biopharma: first patient dosed in US Phase II/III COVID-19 RHB-107 study

RedHill Biopharma, a specialty biopharmaceutical company, has announced that the first patient was dosed in its US Phase II/III study of orally-administered RHB-107 (upamostat)[i], an investigational new drug for patients with symptomatic COVID-19 who do not require hospital care. Dror Ben-Asher, RedHill’s CEO said: “RedHill is rapidly advancing two Phase… Read More

#Covid-19 #News

#AI / data analytics / healthtech / informatics #Clinical trials #Drug discovery #Pharmaceuticals #Rare disease #Therapeutics

The move towards patient-powered, data-driven rare disease drug discovery

By Rayne Rodgers, Vice President and Executive Director of MOVR for Muscular Dystrophy Association (MDA), and Sharon Hesterlee MDA’s Executive Vice President and Chief Research Officer. As an umbrella organisation representing those living with more than 40 types of neuromuscular disorders, the Muscular Dystrophy Association (MDA) contributes significantly to innovations… Read More

#Editor's Choice #Exclusive Content #News

#AI / data analytics / healthtech / informatics #Drug discovery #Therapeutics

Exscientia and University of Oxford partner on AI-driven Alzheimer’s treatments

Exscientia, an AI drug discovery company, has announced its collaboration with the Alzheimer’s Research UK University of Oxford Drug Discovery Institute (ARUK-ODDI) to develop medicines targeting neuroinflammation for the treatment of Alzheimer’s disease (AD). AD is the most common form of dementia worldwide, with an estimated 44 million people living… Read More

#Editor's Choice #News

#Assay development & optimisation #Drug discovery #Therapeutics

PerkinElmer launches assay kits to help advance therapeutics discovery

PerkinElmer has announced the addition of new assay kits to help further GPCR (G Protein-Coupled Receptor) therapeutic discovery. The new offerings extend the company’s GPCR analysis portfolio, which includes assays, plate readers, automation technologies and software solutions combined with siRNA, shRNA, CRISPR, and cDNA/ORF libraries to help scientists more easily… Read More

#News

#Gene editing #iPSC #Therapeutics

Horizon applies expertise for iPSC cell line engineering services

The development of therapeutic treatments is a challenging process linked to understanding mechanisms that underly human disorders. Finding the relevant biological model has been a limiting process so far. The development of induced pluripotent stem cell (iPSC) technology has revolutionised the way we study complex disorders. iPSCs offer a unique… Read More

#News